Published in Fortschr Med on November 07, 1985
Drug interactions with cimetidine. Clin Pharmacokinet (1982) 2.49
Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol (1981) 1.86
Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46
Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet (1980) 1.42
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
[The duodenojejunal flexure--a gap in the routine diagnosis of gastrointestinal bleeding]. Dtsch Med Wochenschr (1999) 1.38
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet (1984) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther (1981) 1.29
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol (1986) 1.06
Pharmacokinetics of ketamine in man. Anaesthesist (1975) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet (2005) 0.98
Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut (1987) 0.97
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med (1974) 0.90
Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol (1982) 0.90
Omeprazole inhibits elimination of diazepam. Lancet (1984) 0.90
Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1980) 0.90
Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther (1978) 0.89
In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology (1985) 0.88
[Familial dwarfism with disproportionately high vertebral bodies]. Humangenetik (1972) 0.87
Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) (1984) 0.87
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol (1984) 0.87
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol (1985) 0.86
Disposition of valproic acid in man. Eur J Clin Pharmacol (1977) 0.85
Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol (1978) 0.83
Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clin Pharmacol Ther (1982) 0.83
Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther (1987) 0.83
[Purification and characterization of a 3'-phosphoadenylylsulfate: steroid sulfotransferase from human liver]. Biochim Biophys Acta (1970) 0.83
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat (2004) 0.82
Sensitive high-performance liquid chromatographic method for the determination of metronidazole and metabolites. J Chromatogr (1983) 0.82
[Drugs interacting with coumarine oral anticoagulants (author's transl)]. Klin Wochenschr (1973) 0.82
Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci (1994) 0.82
Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J (1984) 0.82
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Ultrasound-guided emergency endoscopic retrograde biliary drainage without radiography. Endoscopy (1997) 0.81
Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klin Wochenschr (1985) 0.80
Analysis of DNA strand breaks, oxidized bases, and glutathione S-transferase P1 in human colon cells from biopsies. Cancer Epidemiol Biomarkers Prev (1999) 0.79
[Incidence of catechol-O-methyltransferase in human erythrocytes]. Arch Int Pharmacodyn Ther (1973) 0.79
Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists. Klin Wochenschr (1985) 0.79
[Frequency of surgery in ulcer after the introduction of H2-blockers]. Dtsch Med Wochenschr (1984) 0.78
[Granulomatous colitis with pseudopolyp in schistosomiasis]. Dtsch Med Wochenschr (1989) 0.78
[Treatment failure of cimetidine in duodenal ulcer (author's transl)]. Dtsch Med Wochenschr (1982) 0.78
[Purification and characterization of human placenta S-adenosylmethionine:catechol-O-methyltransferase]. Biochim Biophys Acta (1970) 0.78
Influence of phenobarbital treatment on cimetidine kinetics. Eur J Clin Pharmacol (1981) 0.78
Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepatogastroenterology (1999) 0.77
The pharmacokinetic properties of beta adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.77
Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther (1983) 0.77
Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr (1985) 0.77
Clinical pharmacokinetics of hypolipidaemic drugs. Clin Pharmacokinet (1979) 0.76
Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther (1985) 0.76
Cimetidine excretion into breast milk. Br J Clin Pharmacol (1979) 0.76
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol (1992) 0.76
Cimetidine disposition in obesity. Am J Gastroenterol (1984) 0.76
Altered disposition and availability of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol (1982) 0.75
Different iron-chelating properties of aminosalicylates. Gastroenterology (1992) 0.75
A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol (1981) 0.75
[Relationship between the blood level and the inhibitory effect of renin activation under beta-receptor blockade using pindolol]. Verh Dtsch Ges Inn Med (1976) 0.75
[Influence of thyroid function on human drug metabolism]. Verh Dtsch Ges Inn Med (1973) 0.75
[Studies on gastric acid secretion following Pentagastrin administration]. Verh Dtsch Ges Inn Med (1968) 0.75
[Alcohol and drugs, physician and patient]. Med Welt (1968) 0.75
Pneumoperitoneum following colonoscopy in a patient with a solitary rectal ulcer. Endoscopy (1991) 0.75
[Topic Complex IV: Erosive reflux disease (ERD)]. Z Gastroenterol (2005) 0.75
[Indications and successes of conservative therapy in gastroenterology: peptic ulcer]. Z Gastroenterol Verh (1989) 0.75
Proceedings: Pharmacokinetics of drugs in patients with nephrotic syndrome. Arzneimittelforschung (1976) 0.75
Pharmacokinetics of practolol in renal failure. Eur J Clin Pharmacol (1974) 0.75
A rapid gas chromatographic method for the determination of chlorophenoxyisobutyric acid in plasma and urine. J Chromatogr (1976) 0.75
Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. Clin Sci Mol Med Suppl (1976) 0.75
[Plasma level of pindolol (Visken) under long-term treatment, computed from pharmacokinetics after a single dose]. Verh Dtsch Ges Inn Med (1976) 0.75
[Peptic ulcer. New H2 blockers, prostaglandins, benzimidazoles]. Fortschr Med (1987) 0.75
[The value of x-ray signs in the follow-up of Crohn's disease]. Rofo (1989) 0.75
[A young diabetic with small-nodule liver cirrhosis, high transferrin saturation and negative HFE test]. Dtsch Med Wochenschr (2005) 0.75
Proceedings: Alterations in the pharmacokinetics of drugs by portocaval shunt. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.75
Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man. Arzneimittelforschung (1975) 0.75
Interlaboratory variability of valproic acid determinations. Arzneimittelforschung (1977) 0.75
[Letter: Drug interactions]. Dtsch Med Wochenschr (1974) 0.75
Sensitive fluorometric method for determination of quercetin in plasma or urine. Clin Chem (1973) 0.75
[Rational diagnosis in gastroenterology: current status and perspectives. The stomach and duodenum]. Z Gastroenterol Verh (1990) 0.75
[The "Heidelberg model" of a program for continuing education]. Med Welt (1967) 0.75
Inhibition of human liver catechol-O-methyltransferase by flavonoids. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.75
Can cyclosporin prevent proctocolectomy in severe steroid-refractory ulcerative colitis? Lessons from a case report. Dig Dis Sci (1993) 0.75
[Gastrointestinal diseases: patients ask the expert. Surgical possibilities in Crohn disease and ulcerative colitis--2]. Fortschr Med (1988) 0.75
[Antipyrine excretion and aminopyrine breath test: use and significance in the assessment of liver function]. Z Gastroenterol (1987) 0.75
Proceedings: Effect of portosystemic shunting on the distribution of drugs. Arzneimittelforschung (1976) 0.75
Endoscopic management of toxic masses in stomach. N Engl J Med (1977) 0.75
Effect of an aluminium-hydroxide containing antacid on the oral bioavailability of pirenzepine. Arzneimittelforschung (1989) 0.75
[Influencing the effect of oral anticoagulants by other drugs]. Med Welt (1974) 0.75
The clinical use of plasma drug concentrations. Ration Drug Ther (1976) 0.75